Company news
Jade Biosciences, Inc. (NASDAQ:JBIO) news
Jade Biosciences, Inc. news releases on 6ix. Latest, Jan 23, 2023: Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
Press releases — page 2
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
January 22, 2023
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
November 16, 2022
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
November 13, 2022
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
October 17, 2022
Aerovate Therapeutics Announces Second Quarter 2022 Financial Results
August 14, 2022
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
May 15, 2022
Aerovate Therapeutics Announces First Quarter 2022 Financial Results
May 15, 2022
Aerovate Therapeutics Announces Full-Year 2021 Financial Results
March 29, 2022
Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference
March 1, 2022
Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension
December 14, 2021
Aerovate Therapeutics Announces Third Quarter 2021 Financial Results
November 14, 2021
Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index
September 16, 2021
Aerovate Therapeutics Announces Second Quarter 2021 Financial Results
August 15, 2021
Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors
July 18, 2021
Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
July 1, 2021
Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering
June 28, 2021